ARCHIVES

Zaltrap Economics 101: The Pricing And Repricing of an Expensive Drug

This article is from The Cancer Letter archive.

Vol. 38 No. 43 | November 16, 2012

Download PDF Visit The Full Archive

Related Articles

Hopkins Begins Review Of All Studies After OHRP Lifts Research Suspension.

July 27, 2001

In Congress: NCI Defends Role of Advisor In Response To House Inquiry

September 19, 1997

DRCCA Bard Group Recommends No New Nationwide Screening Program Until More Research Is Done

November 5, 1982

In Brief: Geza Jak Reportedly Picked For Cancer Panel; Supreme Court To Hear Cigarette Label Case

April 12, 1991

Fidaxomicin for CDI Therapy More Cost-Effective Than Vancomycin, Study Says

September 26, 2014

Trial In Metastatic Disease To Be Unblinded After Regorafenib Meets Primary Endpoint

November 25, 2011